Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana serotype) in pigs.

Morozov I, Davis AS, Ellsworth S, Trujillo JD, McDowell C, Shivanna V, Dasen EJ, Nichols R, Martin BK, Monath TP, Richt JA.

J Gen Virol. 2019 Nov;100(11):1478-1490. doi: 10.1099/jgv.0.001329.

PMID:
31553299
2.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

3.

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

Chen WA, Zhang J, Hall KM, Martin CB, Kisselev S, Dasen EJ, Vahanian NN, Link CJ, Martin BK.

PLoS One. 2017 Aug 7;12(8):e0182683. doi: 10.1371/journal.pone.0182683. eCollection 2017.

4.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
5.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

6.

c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes.

Fraczek LA, Martin CB, Martin BK.

Mol Immunol. 2011 Oct;49(1-2):201-10. doi: 10.1016/j.molimm.2011.08.013. Epub 2011 Sep 14.

7.

Transcriptional control of genes for soluble complement cascade regulatory proteins.

Fraczek LA, Martin BK.

Mol Immunol. 2010 Nov-Dec;48(1-3):9-13. doi: 10.1016/j.molimm.2010.08.016. Epub 2010 Sep 25. Review.

PMID:
20869772
8.

CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.

Ingersoll SA, Martin CB, Barnum SR, Martin BK.

Mol Immunol. 2010 Nov-Dec;48(1-3):219-30. doi: 10.1016/j.molimm.2010.08.007. Epub 2010 Sep 1.

9.

Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Holbrook MR, Martin BK, Vahanian N, Link CJ, Flick R.

J Virol Methods. 2010 Nov;169(2):259-68. doi: 10.1016/j.jviromet.2010.07.015. Epub 2010 Jul 22.

PMID:
20655330
10.

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R.

Virology. 2010 Feb 5;397(1):187-98. doi: 10.1016/j.virol.2009.11.001. Epub 2009 Nov 24.

11.

Transcriptional control of complement receptor gene expression.

Martin BK.

Immunol Res. 2007;39(1-3):146-59. Review.

PMID:
17917062
12.
13.

Transcriptional control of the C3a receptor gene in glial cells: Dependence upon AP-1 but not Ets.

Martin CB, Ingersoll SA, Martin BK.

Mol Immunol. 2007 Feb;44(5):703-12. Epub 2006 Jul 18.

PMID:
16854466
14.

Regulation of the C5a receptor promoter in glial cells: Minimal dependence upon the CCAAT element in astrocytes.

Martin CB, Ingersoll SA, Martin BK.

Mol Immunol. 2007 Feb;44(5):713-21. Epub 2006 Jun 5.

PMID:
16750856
15.

Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis.

Reiman R, Campos Torres A, Martin BK, Ting JP, Campbell IL, Barnum SR.

Neurosci Lett. 2005 Dec 30;390(3):134-8. Epub 2005 Sep 9.

PMID:
16154690
17.
18.

Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle.

Kim DY, Martin CB, Lee SN, Martin BK.

Cancer Immunol Immunother. 2005 Oct;54(10):1026-37. Epub 2005 May 3.

PMID:
15868168

Supplemental Content

Loading ...
Support Center